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ENGLISH SUMMARY 
Over the last decades, the prevalence of overweight and obesity have increased and 
grown to be an important health concern worldwide. Obesity is associated with 
increased risk of type II diabetes (DM II), cardiovascular diseases (CVD), stroke, 
myocardial infarction (MI), hypertension, heart failure (HF) and cardiovascular 
mortality. However, the prognostic influence of obesity on mortality among patients 
with manifest coronary artery disease (CAD) is still controversial. 
Guidelines recommend weight reduction for overweight and obese patients with 
CAD. While obesity is a risk factor for developing CAD, obese patients with 
established CAD have reduced mortality risk compared to patients with normal 
weight. This phenomenon has been called “the obesity paradox” and has fueled 
many discussions among epidemiologists as to whether this relation is causal.  
By linkage of the Danish Coronary Angiography Registries and the National Patient 
Registry, National Prescription Registry, Danish Register of Causes of Death, and 
the Danish Civil Registration System, we have been able to examine the association 
between obesity and mortality in patients with established CAD. 
 
The aims of the present thesis were to examine the following questions in patients 
with established CAD:  
1. Is overweight and obesity associated with increased mortality?  
2. Is weight gain associated with reduced mortality?  
3. Is low BMI associated with reduced risk of developing HF? 
The main finding of the first study was that overweight patients with CAD have 
improved survival compared to normal weight patients. Underweight and severely 
obese patients have increased risk of mortality. The study demonstrated the presence 
of an overweight paradox rather than an obesity paradox. The second study 
demonstrated that overweight subjects whose weight remained stable had decreased 
risk of mortality compared to normal weight patients with stable weight. Weight 
gain or weight loss was not associated with change in mortality risk for overweight 
and obese patients. The last study illustrated that the risk of developing HF in 
patients with CAD increases noticeably for underweight and obese patients. On the 
other hand, overweight subjects had the lowest incidence of HF. 
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DANSK RESUME 
I de sidste årtier er forekomsten af overvægt og fedme øget, og det udgør et stigende 
sundhedsproblem på verdensplan. Fedme er forbundet med type II-diabetes (DM II), 
apopleksi, myokardieinfarkt (MI), hypertension, hjertesvigt (HF) og kardiovaskulær 
mortalitet. Alligevel betydningen af overvægt for dødeligheden hos patienter med 
koronararteriesygdom (CAD) er stadig omdiskuteret. 
Der er evidens for at fedme er en risikofaktor for udvikling af CAD og retningslinjer 
anbefaler vægttab for overvægtige og svært overvægtige patienter. Dog har man 
observeret en lavere dødelighed blandt svært overvægtige patienter med CVD 
sammenlignet med normalvægtige. Dette fænomen er blevet kaldt fedme paradokset 
og det vakte epidemiologernes opmærksomhed. 
I denne afhandling har vi koblet de danske koronarangiografi registre sammen med 
andre registre; Landspatientregistret, Lægemiddelregistret, danske register over 
dødsårsager og det danske Centrale Personregister for at undersøge sammenhængen 
mellem fedme og mortalitet hos patienter med CAD. 
Formålene med denne afhandling var at undersøge; 
1. Er overvægt og fedme forbundet med øget dødelighed? 
2. Er vægtøgning hos patienter med CAD forbundet med reduceret dødelighed? 
3. Er lavt BMI forbundet med reduceret risiko for at udvikle HF? 
De vigtigste resultater fra den første undersøgelse viste, at overvægtige patienter 
med CAD har bedre overlevelse sammenlignet med normalvægtige patienter. 
Undervægtige og svært overvægtige patienter har øget risiko for dødelighed. Vores 
resultater bekræftede et overvægts paradoks snarere end en fedme paradoks. Den 
anden undersøgelse viste, at overvægtige patienter som holder deres vægt stabil, har 
mindre risiko for dødelighed sammenlignet med normalvægtige patienter med stabil 
vægt. Derimod var vægtøgning og vægttab ikke forbundet med øget risiko for død 
for overvægtige og svær overvægtige patienter. Den sidste undersøgelse viste, at 
risikoen for at udvikle HF hos patienter med CAD har steget mærkbart for de 
undervægtige og svær overvægtige patienter. Derimod havde de overvægtige den 
laveste risiko for udvikling af HF sammenlignet med de andre BMI grupper. 
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ABBREVIATIONS 
CAD                    Coronary artery disease   
CVD    Cardiovascular disease 
DM                      Diabetes mellitus  
HF                       Heart failure 
BMI                     Body mass index 
CRF                     Cardiorespiratory fitness 
CI    Confidence interval 
HR    Hazard ratio 
ICD    International Classification of Diseases 
IRs                      Incidence rates 
MI   Myocardial infarction 
WHO                   World Health Organisation 
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INTRODUCTION 
According to the World Health Organization (WHO), overweight and obesity are 
defined as increased fat accumulation in the body which is higher than is considered 
a healthy weight for a given height. A person with a body mass index (BMI) over 25 
kg/m
2
 is defined as overweight, and a BMI over 30 kg/m
2
 is defined as obese (103). 
BMI is an easy and crude measure of body fat, calculated by dividing the weight in 
kilograms by the square of height in meters however, it does not differentiate 
between body fat and lean mass (1). 
The prevalence of overweight and obesity has increased globally. In 2014, more 
than 1.9 billion adults were considered overweight and over 600 million were obese 
(103). Abnormal fat accumulation constitutes a major health problem, as it is 
associated with increased risk of metabolic and cardiovascular disease. A recent 
study from the United States showed that obesity was the direct cause of 18% of 
deaths from 1986-2006(2). There is evidence that overweight and obesity are risk 
factors of developing cardiovascular disease, type II diabetes, hypertension, 
colorectal cancer, gallbladder cancer, pancreatic cancer, ovarian cancer, heart 
failure, and early death. (3-7).  
Previous studies investigated the relationship between excess body fat and 
cardiovascular disease. They found that obesity leads to cardiovascular disease, 
mediated by an increased risk of acquiring well-known cardiovascular risk factors 
such as, hypertension, dyslipidemia, glucose intolerance, and low-level 
inflammation and atherosclerosis by different pathophysiological pathways (8, 9).  
Atherosclerosis is the primary cause of coronary artery disease. It is described as an 
inflammatory disease in the arterial intima, and is seen even in young people. 
Progression of atherosclerosis initiates with lesions of the artery wall, and includes 
accumulation of lipids, cholesterol, calcium, macrophages, T-cells, and mast cells. 
Over time the artery wall will be covered by collagen, forming a plaque. As the 
plaque hardens and enlarges, the coronary artery gradually narrows, and the blood 
flow to the heart muscle is impaired (10, 11). Early signs of impaired flow includes 
angina and dyspnea, and in cases of plaque rupture, the blood plates clots on its 
surface, leading to total occlusion of the coronary artery, and causing a heart attack. 
By performing a coronary angiography, the stenosis can be verified and further 
treatment such as percutaneous coronary intervention (PCI) can reduce the stenosis.  
However, obesity influences the structure and function of the cardiovascular system 
by increasing the blood and stroke volume, which leads to higher filling pressure 
and volume. Furthermore, the cardiac output increases, leading to higher demands 
on the cardiac system which, over time, causes changes in the left ventricular, 
resulting in hypertrophy and heart failure (12). 
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Despite these adverse effects of obesity, numerous epidemiologic studies have 
demonstrated a phenomenon called the obesity paradox where obese patients with 
cardiovascular disease have lower risk of mortality compared to patients with 
normal weight (1, 13-16).  The obesity paradox has been found among patients with 
atrial fibrillation, hypertension, cardiac surgery, and also patients with chronic 
diseases like diabetes mellitus, chronic kidney disease, and chronic obstructive 
pulmonary disease (17-22). There are also numerous studies which have not 
confirmed the favorable effect of obesity among CVD patients (23-28).  
Some studies have investigated the association between obesity and mortality by 
using BMI as a proxy for obesity and have been criticized as a result, because BMI 
is not a sufficient measure of body fat, since it does not account for body 
composition. Nevertheless, other studies using different measurements like body fat 
and waist circumference have also confirmed the existence of the obesity paradox 
among patients with CVD (29, 30). Even though the obesity paradox phenomenon 
has been known for decades possible explanations have been sparse. Apart from 
possible causality, other explanations are bias, reverse causation, and confounding 
(31-33). Many guidelines recommend weight loss for overweight and obese 
individuals (34, 35). Several studies recommend intentional weight loss as it will 
improve the metabolic syndrome and the prevalence of diabetes mellitus, 
hypertension, and mortality and CVD (36-39). Other recent studies showed that 
overweight individuals with no weight change had better prognosis than normal 
weight patients with no weight change (40-42). 
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OBJECTIVES 
 
1. To explore the obesity paradox among patients with established  CAD, we 
hypothesized that obese patients have better survival compared with normal 
weight patients.  
  
2. To explore the effect of  weight change on mortality among patients with 
CAD, we hypothesized that weight loss will improve the survial chance.  
 
 
3. To explore the risk of incidence HF in patients with CAD, we hypothesized 
that patients with lower BMI have decreased incidence of HF.  
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METHODS 
DATABASES 
The studies of this thesis were based on data from Western Danish Heart Registry, 
and comprising nationwide angiography data, The Civil Person Registry, The 
Prescription Registry, The National Patient Registry and The Causes of Death 
Registry.  The Civil Person Registry provides a unique identification number at birth 
which keeps information on gender and date of birth. This allows individual-level 
linkage across nationwide registries. The National Patient Registry holds 
information on hospital admissions and discharge dates, diagnosed according to the 
International Classification of Diseases (ICD) system, 8
th
 revision (ICD-8) from 
1977 until 1994, and the 10
th
 revision (ICD-10) thereafter. The information on 
prescription drugs, dose and dispensing, obtained from The Danish Prescription 
Registry, are coded according to the Anatomical Therapeutical Chemical (ATC) 
classification since 1995 (43).  
All data were retrieved and analyzed through Statistics Denmark. Statistics Denmark 
prepared the linkage of registries and encoded the identification numbers to ensure 
anonymity.   
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DEFINITION OF COMORBIDITY AND MEDICATION 
Details on medication, comorbidity are listed in Table 1.   
Pharmacotherapy ATC codes: 
Loop diuretics C03C 
Beta blockers C07 
ACE inhibitors/ARBs C09 
Comorbidities ICD codes: 
Periphery vascular disease I70-3, R02, I771,  
Heart failure 
I110, I130, I132, J819, I517, I42, 
I43, I50, 427 
Cerebral vascular disease I60-9,411-4 
Chronic obstructive pulmonary 
disease J42-4, 490-2, 
Renal disease 
N03-4, N17-9, R34, I12-3, T858-9, 
Z992,582-8 
liver disease 
K70-7, K766, K711, K704, B150, 
B160, B190, 571-2,456 
Malignancy C00, C97,  
Hypertention 
Defined from combination treatment 
with a least two classes of anti-
hypertensive drugs 
Hyperlipidaemia Defined from treatment with statin  
Arrhythmia I46-49, 4273-9 
Ischemic heart disease I20, I23-5, 411-4 
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COHORTS AND OUTCOMES 
PAPERS I+II: RISK OF ALL-CAUSE MORTALITY 
The population in study I were patients with verified coronary artery disease 
between 1 January 2000 and 31 December 2010, and in paper II between 1 January 
2000 and 31 December 2012. Subjects with no vessel disease, and those lacking 
information on weight or height were excluded. In Paper II all patients with weight 
change within the first 6 months of follow-up were excluded. We have adjusted for 
chronic obstructive pulmonary disease, renal disease, liver disease, prior heart 
disease, stroke, malignancy, and family history of coronary artery disease (including 
severity), diabetes, hyperlipidemia, hypertension, and smoking status. In paper I, we 
divided the study population according to WHO classification of BMI and chose 
normal weight class II (BMI: 23-25 kg/m2) as the reference group. In paper II, all 
patients have been divided in four BMI classes then being further divided into three 
weight categories.  Our reference group was of stable, normal weight. 
 
PAPER III: RISK OF HEART FAILURE 
The population of this study included all patients with coronary heart disease 
verified by coronary angiography between 1 January 1998 and 31 December 2012. 
We included all subjects who got their first prescription of loop diuretic medicament 
three months after their hospital discharge. We adjusted for chronic obstructive 
pulmonary disease, renal disease, liver disease, peripheral artery disease, cerebral 
artery disease, malignancy, and family disposition for ischemic heart disease, as well 
as age and sex. Additional information on comorbidities such as weight, height, 
diabetes, Statin treatment, Hypertension treatment, smoking status, indication of 
coronary angiography and severity of coronary artery disease determined by 
coronary angiography (0, 1, 2, or 3 vessel disease, multi vessel [≥2] disease, and 
diffuse [≤50% stenosis] disease, respectively were obtained from Danish 
angiography registries. Patients with HF were identified by using treatment with 
loop diuretics, including furosemide (ATC code C03CA01) and bumetanide 
(C03CA02) as a proxy. We also included data on filled prescriptions of common 
types of drugs used in treatment of HF, including β-blockers (C07) and angiotensin-
converting enzyme (ACE) inhibitors (C09AA). The study population has been 
divided into five BMI groups. The reference group was of normal weight (BMI: 20-
25).  
 17 
STATISTICAL ANALYSES 
All statistical analyses were done with the SAS statistical software version 9.2 (SAS 
Institute Inc., Cary, NC), Stata software version 11 (Statacorp, College St., TX) and 
R software version 3.2.2. 
Data were presented as categorical variables with numbers and percentages, and 
continuous variables as means with standard deviation. In paper I-II the incidence 
rates (IRs) of death were presented per 1000 person-years. We used survival 
analysis to calculate the difference in survival associated with BMI and weight 
classes. The Kaplan-Meier estimates gave us a graphic presentation of survival in 
different BMI groups. The outcomes were estimated by Cox proportional hazard 
regression models. In paper III, the cumulative incidence of HF taking into account 
a competing risk for non-HF death was calculated by using the Aalen-Johansen 
method. Hazard ratios (HRs) with mortality as a competing risk for the study 
outcome were estimated with a modified Cox proportional hazard regression 
analysis (cause-specific proportional hazards model) adjusted for comorbidities. 
Model assumptions, linearity of continuous variables, fulfillment of the proportional 
hazard assumption and lack of relevant interactions were tested and found to be 
valid. 
 
ETHICS 
The research protocol was approved by the Faculty of Health Sciences, University 
of Aalborg. In Denmark, registry based studies do not require ethical approval and 
the Danish Data Protection Agency permitted the study (reference no. 2007-58-
0015, international reference: GEH-2014-015). 
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TABLE 2. SUMMARY OF METHODS USED IN THE INDIVIDUAL 
STUDIES. FOR ABBREVIATIONS, SEE TEXT. 
 
 
 
 
  
Paper I 
 
Paper II 
 
Paper III 
Study objective 
To investigate the 
influence of obesity 
on survival in 
patients with CAD. 
To explore the effect 
of weight change 
over time on survival 
in patients with CAD. 
To investigate the 
effect of obesity on 
incidence of heart 
failure in patients 
with CAD. 
 
Design 
Register-based cohort 
study of patients with 
coronary artery 
disease from The 
Western Denmark 
Heart Registry  
 
Register-based cohort 
study of patients with 
coronary artery 
disease from entire 
Danish Heart Center. 
Register-based cohort 
study of patients with 
coronary artery 
disease from entire 
Danish heart centers. 
Study period 2000-2010 2000-2012 1998-2012 
N 37 573 7 683 32 545 
Exclusion criteria Subjects with missing 
information about 
height, weight, 
degree of the vessel 
disease, prior cardiac 
surgery or 
percutaneous 
coronary intervention 
and no vessel were 
excluded. 
Patients with missing 
information about 
weight or height, 
weight change within 
6 months, no vessel 
disease were 
excluded. 
 
Subjects with missing 
information on 
weight, height, 
degree of vessel 
disease, prior HF or 
received loop 
diuretics before the 
date of coronary 
angiography and no 
vessel were excluded. 
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Paper I 
 
Paper II 
 
Paper III 
Outcomes 
 
All-cause mortality All-cause mortality The incidence of HF 
and all-cause 
mortality 
 
 
Covariates 
Age, sex, smoking, 
diabetes, degree of 
vessel disease, 
hypertension, 
hyperlipidemia, 
serum creatinine, 
arrhythmia, 
periphery vascular 
disease, cerebral 
vascular disease, 
heart failure, 
chronic obstructive 
lung disease, cancer, 
prior MI.  
Age, sex, smoking, 
diabetes, degree of 
vessel disease, 
hypertension, 
hyperlipidemia, 
family history of 
ischemic heart 
disease, heart 
failure, malignancy, 
chronic obstructive 
lung disease, 
cerebral vascular 
disease, periphery 
vascular disease, 
arrhythmia, renal 
disease and liver 
disease. 
Chronic obstructive 
pulmonary disease, 
renal disease, liver 
disease, Arrhythmia, 
degree of vessel 
disease, diabetes, 
hyperlipidemia, 
hypertension, 
smoking status,  
Indication for 
coronary 
angiography, sex and 
age, cerebral vascular 
disease, malignancy, 
and family 
disposition for 
ischemic heart 
disease.  
 
Statistical 
analyses 
Cox proportional 
hazard regression 
models to estimate 
HR, Kaplan-Meier 
estimates.  
Cox proportional 
hazard regression 
models to estimate 
HR, and IR.  
Modified Cox 
proportional hazard 
regression analysis 
(cause-specific 
proportional hazards 
model). Cumulative 
incidence 
calculations.  
Main results Overweight patients 
with CAD had an 
improved survival 
compared with 
normal weight 
patients. 
Underweight and 
severely obese 
patients had 
increased risk of 
mortality. 
We confirmed the 
overweight paradox 
among this group of 
patients. 
Overweight subjects 
with stable weight 
had decreased risk 
of mortality 
compared with 
normal weight 
patients with stable 
weight. On the other 
hand, weight loss in 
underweight and 
normal weight 
subjects was 
associated with 
increased risk of 
mortality. 
The risk of 
developing HF in 
patients with CAD 
increased with 
obesity and 
underweight. 
Contrariwise, 
overweight patients 
had the lowest risk of 
HF after normal 
weight patients.  
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RESULTS 
This section provides the main findings of each paper. 
PAPER I: MODERATE OVERWEIGHT IS BENEFICIAL AND 
SEVERE OBESITY DETRIMENTAL FOR PATIENTS   WITH 
DOCUMENTED ATHEROSCLEROTIC HEART DISEASE. 
The objective of this study was to examine the obesity paradox among patients with 
coronary artery disease.  
From 2000-2010 100128 patients who underwent coronary angiography were 
identified and 37573 patients were the final population of the study (Figure 1). 
The mean age was 66.3 (±11) years and 26540 (70.7%) were men. The median 
follow-up time was 3.2 years and 5866 (15.6%) patients died. The study showed that 
there was a significant higher mortality risk of (HR 2.04, 95% CI, 1.63 - 2.57; 
p<0.001) for the underweight group (BMI < 18.5 kg/m
2
) compared to the reference 
group of normal weight class II (23 ≤ BMI < 25 kg/m2). The pre-obese (27.50 ≤ 
BMI < 30 kg/m
2
) had a decreased risk, with a HR: of 0.82 (95% CI 0.71 - 0.95; P= 
0.008).The normal weight class I (18.5 ≤ BMI < 23 kg/m2) had noteworthy risk of 
mortality HR 1.28 (95% CI, 1.13 - 1.45; p< 0.001). The obese class III (BMI ≥ 40 
kg/m
2
) patients had an increased HR of 1.35 (95% CI, 1.05 - 1.72; p= 0.016) Figure 
2.  
The conclusions from these findings were that overweight patients class II (27.5 ≤ 
BMI < 30 kg/m
2) had better survival compared to normal weight class II (23 ≤ BMI 
< 25 kg/ m
2
), on the other hand patients in normal weight class I (18.5-23 kg/m
2
 ) 
and obese class II (BMI > 40 kg/m
2
) had increased risk of mortality compared to 
normal weigh. Our results pointed towards an overweight paradox rather than an 
obesity paradox. 
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Figure 1 Flowchart of the study population in paper I 
 
 
Figure 2. Adjusted hazard ratio of all-cause mortality in different BMI groups and the normal 
weight (BMI: 23-25 kg/m2) as the reference group.  
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PAPER II: IMPACT OF WEIGHT LOSS AND WEIGHT GAIN ON 
MORTALITY RISK IN PATIENTS WITH CORONARY HEART DISEASE. 
The aim of this study was to explore the impact of weight change on risk of 
mortality over time among patients with coronary artery disease.    
In this study we enrolled all patients (n= 42372) with two coronary angiographies at 
two different times. We divided each BMI group into three weight change groups: 
weight gain, weight loss and stable weight (Figure 3). 
The results showed that overweight patients with stable weight had an 18% lower 
risk of mortality (HR 0.82; 95% CI 0.6–0.9, P=0.04) compared to those with stable 
weight and normal BMI. We concluded that, overweight patients with stable weight 
had significantly decreased risk of mortality compared to normal weight patients 
with stable weight. The weight loss group had more tendencies towards high risk of 
mortality than stable weight (Figure 4). 
 
  Figure 3 Flowchart of the study population in paper II 
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Figure 4 Association between weight classes and risk of all-cause mortality. 
Adjusted for; age, sex, smoking, diabetes, degree of vessel disease, hypertension, 
hyperlipidemia, family history of coronary artery disease, heart failure, malignancy, chronic 
obstructive lung disease, cerebral vascular disease, periphery vascular disease, arrhythmia, 
renal disease, liver disease 
 
 
 
PAPER III: RISK OF HEART FAILURE IN PATIENTS WITH CORONARY 
HEART DISEASE. 
In this study we investigated the risk of heart failure in patients with coronary artery 
disease. We included a total of 31881 subjects, where 5980 developed HF during the 
15 year follow up period. When patients were divided into five groups according to 
their BMI (Figure 5), we found that the risk of developing HF was increased in 
patients with higher BMI rates than those with normal BMI. The overweight group 
had the lowest risk of HF after the normal weight group (Figure 6). On the other 
hand the unadjusted cumulative risk of mortality increased as BMI decreased. 
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Figure 5 Flowchart of the study population in paper III 
 
 
Figure 6 Association between body mass index (BMI) and risk of heart failure determined by 
use of loop diuretics. Results adjusted for age, sex, chronic obstructive pulmonary disease, 
renal disease, liver disease, prior heart disease, degree of vessel disease, diabetes, 
hyperlipidemia, hypertension, smoking status, stroke, malignancy, and family history of 
ischemic heart disease. 
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DISCUSSION  
In this thesis, we examined the association between weight/BMI, and mortality and 
incidence of heart failure. Our main findings were that moderate overweight in 
patients with established coronary heart disease was associated with lower risk of 
mortality compared to normal weight patients. On the other hand, underweight and 
obese patients had a higher risk of mortality. We further looked at weight change 
and risk of mortality among this group of patients and found that overweight 
patients who had stable weight had decreased risk of mortality compared to patients 
with normal weight and stable weight. We looked at the incidence of onset HF 
among coronary artery population and the results showed that overweight subjects 
had the lowest risk of HF. However, the risk increased significantly for subjects with 
BMI over 30kg/m
2
. Overweight and obese patients who developed HF were at lower 
risk for mortality compared to those of normal weight.  
 
 
OBESITY AND CARDIOVASCULAR DISEASE 
Obesity is a worldwide public health problem and the prevalence is growing. There 
is increasing evidence that obesity is an independent risk factor for developing 
cardiovascular disease, type 2 diabetes, metabolic syndrome, dyslipidemia, and 
hypertension (44, 45). Furthermore, obesity is also related to all-cause mortality (9, 
46).  According to the WHO, half of all deaths in Europe are caused by CVD (104), 
while in the USA, CVD is a leading cause of death (47).  
 
OBESITY PARADOX 
In spite of obesity being a well-known cardiovascular risk factor, over the last three 
decades, there have been numerous studies that confirmed the existence of the 
obesity paradox – the fact that obese patients have better survival than their normal 
weight counterparts (1, 48-61).  
We aimed to evaluate the impact of overweight and obesity on mortality and 
incidence of heart failure in a large cohort of patients with established coronary heart 
disease. 
In paper 1, our main finding was that only overweight patients (27.5 ≤ BMI < 30 
kg/m2) had decreased risk of mortality compared to normal weight (23 ≤ BMI < 25 
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kg/ m2). In contrast, severely obese patients (BMI > 40 kg/m2) had increased risk of 
mortality (15). Our finding confirmed the previous finding, that overweight patients 
had decreased risk of mortality (1, 62). 
This study was done by using BMI as a proxy for obesity and found a J-shape 
relationship between BMI and all-cause mortality. Furthermore, we found increased 
risk of mortality for obese patients, even though previous studies have reported good 
prognosis for this group of patients. In this study, our reference group was patients 
with a BMI between 23.5-25 kg/m
2
, which is a normal weight, intended to reflect the 
healthiest patients in the study population with respect to BMI. BMI is widely used 
as a measurement for weight scale, and the weight management recommendations 
are that people should maintain their BMI between 20-25 kg/m
2
. This 
recommendation is for all age groups with no distinction between young, old, 
healthy, or people with established diseases. 
Despite the obesity paradox evidence, several studies have questioned its existence 
and presented possible explanations of their own. Explanations include confounding, 
reverse causality, stating that a real association between weight/ BMI and mortality 
was nonexistent. A recent study found that in a CVD population, normal weight 
patients that were formerly overweight or obese had a higher rate of mortality 
compared to overweight patients with CVD. Conversely, normal weight patients 
with stable weight had lower mortality rates compared to patients who were always 
overweight (63). The same finding appeared in a population of smokers with CVD 
suggesting that weight loss could be due to an undiagnosed disease, which resulted 
in the weight loss and an increased risk of mortality. Therefore, the overweight 
patients appeared to have better survival. The author explained the obesity paradox 
as a product of reverse causality and confounding by smoking (63). Reverse 
causation means that the BMI and mortality relation can be biased by pre-existing 
obesity-related disease resulting in weight loss. Reverse causation has been used as 
explanation for obesity paradox in several studies and it has been pointed out that 
the reverse causation should be taken into account in interpretation of the results of 
the obesity and mortality studies (64-66).  
Another study investigated the association between dysglycemia and mortality, and 
found that among normal-weight subjects with dysglycemia, there were more 
smokers than in the overweight group. The other finding was that normal weight 
subjects who smoked had a higher rate of mortality than overweight smokers. On the 
over hand, the normal weight group who never smoked, had a lower mortality rate 
than the overweight group who never smoked (67). In our studies, the current 
smokers in population paper I and III were more often normal weight than 
overweight and obese. In paper II, the proportion of current smokers in the 
overweight and obese groups was higher than in the normal weight. The number of 
former smokers appeared to be higher in the overweight and obese groups in all 
three populations. One explanation could be the fact that being diagnosed with a 
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severe disease make patients reflect more on their health, motivating them to change 
their lifestyle and comply with treatment recommendations. There are studies which 
reported that obese patients, due to better medication and better compliance with 
guideline recommendations, decreased their risk of morbidities and mortality, 
providing an explanation for the obesity paradox (68-72). 
Another explanation might be age; many studies included younger obese and older, 
normal, or underweight patients. The older population has experienced more illness 
and disease than the younger population (73-76). In our population, the obese 
subjects were at least 8 years younger than the underweight, but the obese suffered 
more often from hypertension, hyperlipidaemia and diabetes. 
Another potential explanation could be selection bias, which suggests that the 
population of obese patients had been treated earlier and therefore has less severe 
diseases. This leads us to think that the healthiest obese will be included in the 
study. Alternatively, the possibility of selection bias occurs when exposure and 
outcome both influence what is to be included in the study (77-79). In our case, 
obesity is a major risk factor of CAD as well as death. There are also other risk 
factors which increase the risk of mortality. If these risk factors are undiagnosed and 
have higher impact on mortality than obesity, then obese subjects might have better 
survival than their normal counterparts.  Another explanation could be survival bias 
in middle-aged overweight or obese subjects, suggesting that obesity intolerance 
leads to low survival rates and greater incidence of CAD. It is also notable to 
mention lead time bias in overweight and obese patients who get CAD diagnosis at a 
younger age, enabling them to begin treatment earlier than normal weight patients. 
This time between diagnose and mortality is longer for overweight or obese than in 
normal weight subjects.  
  
 
Weight change  
In paper II, we discussed the association between weight change and mortality risk 
in patients with coronary artery disease. Our main findings were that overweight 
patients with stable weight had a significantly reduced risk of mortality compared to 
patients with normal and stable weight. Many researchers recommend intentional 
weight loss to decrease risk of mortality, CVD and other comorbidity in overweight 
individuals (80-83). In a recent randomized controlled trial that examined the impact 
of weight loss through caloric restriction on cardiovascular disease morbidity and 
mortality in type 2 diabetes patients, improved outcomes were reported on some 
conditions such as medication usage, depression, sleep apnea and CVD (84). 
However, other recent studies did not find benefit of weight loss (85, 86). 
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Additionally, a recent Danish study which investigated the impact of intentional 
weight loss on mortality and risk of CVD in type 2 diabetes patients found that 
weight loss did not lower their risk of CVD and mortality (87). 
Furthermore, some studies have focused on the importance of fat distribution and 
visceral fat rather than weight and BMI as risk indicators (88, 89). Concerning the 
cardiovascular risk, it has been suggested that individuals with abdominal fat have 
higher risk of cardiovascular disease and mortality. The excess abdominal fat is an 
indication of visceral adiposity (90, 91). Another theory suggests that, even though a 
person is overweight, as long he has a good metabolic health and high 
cardiorespiratory fitness (CRF) (better oxygen supply to the skeletal muscles), the 
risk of CVD is lower. Additional research reported that high CRF in patients with 
CVD, despite high BMI and abdominal fat, was beneficial. According to these 
research results, high BMI and abdominal fat stores do not play an important role 
when the CFR is high. The benefits of CRF include better blood lipids and blood 
glucose, lower abdominal fat, decrease high blood pressure and a great influence on 
reducing CVD risk (92-94).  
 
BMI 
Our exposure in the studies has been BMI which is a calculation of bodyweight in 
kilograms divided by the square of body height in meters. In 1972 Ancel Keys 
mentioned for the first time BMI as an index for obesity or fatness (95) however, the 
BMI measurement does not distinguish between muscle, fat or bones. Indeed, young 
people have more muscle mass than middle-aged or old people and when aging the 
muscle mass declines and  the ratio of fat and lean mass will not be the same (96, 
97). Aging also affects the BMI by age-related height decline resulting in an 
increase of the BMI not necessarily caused by an increase in adiposity (98). The 
question is whether it is relevant to use the same BMI scale for all age groups. 
Furthermore, it might even be good for elderly people to be a little overweight since 
the excess fat might be protective in the event that they develop chronic diseases. 
We suggest an age-specific BMI to take into account the age related body changes. 
The studies of the thesis showed that moderate overweight with a BMI between 
27.5-30 kg/m
2
 is favorable for patients with CVD.  
The classification of BMI provided by WHO is widely used and is based on data 
from 1995, 2000 and 2004 (105). On the other hand, there are debates about the 
recommended BMI cut-off point of the WHO classification for overweight, and 
whether age and ethnicity should be take into account. In 2004 a WHO expert 
consultation reported that current WHO cut-off points for overweight and obese are 
not sufficient for all Asians, as the observed risk for obesity related disease are from 
22- 25 kg/m
2
 and for higher risk from 26-31 kg/m
2
 (99). Recently a Danish study 
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showed that over a period of three decades, the BMI association with mortality 
increased by 3.3(100). The optimal BMI for low mortality among disease free 
populations is 27.3 kg/m
2
 for people older than 60 years and 26.1 kg/m
2
 for people 
who have never smoked (100). Their findings are consistent with our findings from 
study I. We found that individuals with a BMI between 27.5-30 kg/m
2 
have the 
lowest mortality rate. The difference is that, while our study population consisted of 
individuals with CAD, and the Danish study population comprised healthy 
individuals, the results are surprisingly, almost similar. Is it time to change cut off 
points for BMI categories? Should we have a new BMI scale taking age, sex and 
ethnicity into account?  
 
 
 
 
STRENGTHS AND LIMITATIONS 
The studies of this thesis were based on the retrospectively recorded data on 
coronary angiography from all cardiovascular intervention centers in Denmark, with 
adjustment for important confounding factors. There are also important limitations 
that should be acknowledged since the studies were not randomized. We had to 
exclude 50% of patients due to lack of information on weight or height, which can 
cause selection bias. In this case it might have been caused by the fact that we have 
included patients who had more frequent contact with the health system, and thus 
registered their weight. Another possible problem is that our studies are 
observational, suggesting the possibility of unmeasured confounders that could 
influence the outcome. In the used registries we lacked information on a variety of 
clinical data, for instance, physical activity, more and exact weight measurements 
(the weight mostly based of self-reported), alcohol intake, nutritional status, and 
other chronic diseases. Another bias that could be important to mention is 
confounding by indication.  Underweight patients were older and more likely to die 
due to illness than normal weight and overweight patients. We used BMI and weight 
as proxies for obesity. The BMI is recognized as a rough indicator of obesity, and 
the use of it as proxy for obesity should be taken with caution, especially in older 
populations. BMI does not provide information about the percentage of fat or its 
distribution in the body. However, studies have suggested that waist to hip ratio, 
waist circumference, the percentage of fat in the body, skinfold thickness, waist-to-
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hip circumference ratio, ultrasound, computed tomography, and magnetic resonance 
imaging are better proxy for obesity. Nevertheless, numerous studies have reported 
that there is a significant relationship between increased BMI and CVD, HF, 
ischemic stroke, and death (101, 102).  
Since we do not have more than one or two weight records during the follow up 
time, we cannot be sure that our reference group has always been of normal weight, 
or if they have ever been overweight/obese previously and may have lost weight due 
to underdiagnosed diseases. 
 
 
 
IMPLICATIONS 
This thesis pointed towards an overweight paradox among patients with coronary 
artery disease, indicate that stable weight is more beneficial than weight change and 
that moderate overweight is protective for CAD patients. As healthcare 
professionals, we should keep in mind that weight management for some patient 
groups are very important. We are also agreeing that the recommendations for 
patients with coronary artery disease should be focused on lifestyle changes rather 
than just BMI changes. On the other hand, we know that BMI is used by healthcare 
and individuals as proxy for obesity and a measurement of health. In this thesis, we 
showed that the ideal BMI for this group of patients is a BMI under 30 kg/m
2
. 
Therefore, we assume that the focus must be pointed towards patients with a BMI 
over 30 kg/m
2
, as they are at greater risk of mortality and HF. 
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FUTURE RESEARCH 
We suggest a prospective study that registers the weight and body fat percentage of 
subjects with different ethnicities in very early life stage and follow them over a 
long period of time to investigate the BMI association with obesity related disease 
and mortality. The focus should not only be on weight, but also on different risk 
factors including mental health, as well as social and economic status, as these 
factors are also important indicators for risk of mortality. The BMI measurement 
does not take the age or other social factors into consideration, which can have an 
influence on health, and as we know, the body composition changes over time. By 
following weight and measuring body fat percentage and other body components 
e.g. muscle and bone, we can investigate if BMI is a reliable tool as a proxy for 
obesity in middle-aged or elderly individuals. This information will provide a good 
base for a new BMI scale or new cut-off points.  
 
 
 
CONCLUSIONS 
The conclusions of this project are that it confirms the existence of an overweight 
paradox in patients with CAD by finding a significant beneficial association 
between overweight and all-cause mortality. The optimal BMI for this group of 
patients is 27.5-30 kg/m
2
. Furthermore, weight management is important for the 
development of HF for patients with CAD. We have to encourage patients with 
coronary artery disease that also have a BMI (>30kg/m
2
) to change their life style as 
they are at higher risk of HF. 
In the end, we concluded that individuals over 60, who are moderately overweight, 
but maintain a stable weight, seem to be the healthiest and have a lower risk of 
mortality and HF, even if they are suffering from chronic disease. We suggest that 
the optimal BMI for middle-age and elderly individual is between 25-30 kg/m
2
. 
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